Kornimate/medical-research-clean huggingface dataset:
impact of minst with and without splinting in periodontitis patients with mobile anterior teeth

Conditions: Tooth Mobility; Periodontitis

Summary: the goal of this clinical trial is to evaluate impact of minimally invasive non-surgical therapy (minst) with and without splinting on clinical periodontal parameters and oral health related quality of life (ohrqol) in periodontitis patients with mobile anterior teeth. the main questions it aims to answer are: * does splinting provide additional benefit to minst alone for improving the clinical periodontal parameters ? * does splinting provide additional benefit to minst alone for improving ohrqol ?

the increased mobility of a periodontally affected tooth can be caused by a shift of centre of rotation of the tooth apically due to clinical attachment loss (cal) and alveolar bone loss (abl) and/or due to secondary occlusal trauma. tooth splinting continues to be a topic of controversy. it remains one of the most poorly understood and controversial areas of dental therapy. minimally invasive non-surgical periodontal therapy (minst) has been introduced for minimizing tissue trauma and enhancing clinical outcomes by the adjunctive use of magnification devices . this study aims to compare clinical periodontal parameters and oral health related quality of life (ohrqol) following minimally invasive non-surgical therapy (minst), both with and without splinting, in patients with stage iii and stage iv periodontitis who have mobile anterior teeth. patients will be screened and enrolled based on specific eligibility criteria. baseline measurements of outcome parameters will be taken, followed by supragingival scaling, and patients will be recalled after one week. during the subsequent visit, patients will be randomized into either the test group or the control group. the test group will receive minst along with splinting of the mobile anterior teeth, while the control group will receive minst alone. patients will be recalled after 8 weeks and 6 months to assess changes in the outcome measurements.

Eligibility criteria:
inclusion criteria: * inclusion criteria at the patient level: systemically healthy patient with presence of stage iii or iv periodontitis, age ≥ 18 years. * tooth-related inclusion criteria: presence of at least one anterior tooth with mobility in combination with a clinical attachment loss (cal) ≥ 5 mm and a relative alveolar bone loss (abl) of ≥ 50% at the affected tooth. * dentition with at least 3 antagonistic contact zones opposing posterior teeth, that is eichner class a1, a2, a3, b1 exclusion criteria: * patients with anterior cross bite * bruxism or signs of parafunction * implant in anterior teeth * any active periodontal therapy in last 1 year * mobility of teeth due to acute trauma * pulpal or periapical pathology in anterior teeth * patient requiring any emergency dental procedure * patient on antibiotic therapy in last 1 month * if patient want to undergo surgical treatment for management of periodontitis.

Keywords: splinting ohrqol minst
study of hbv-001 d1 in healthy adults

Conditions: Dengue Fever

Summary: this is a single-center, double-blind, randomized, phase 1 study to assess the safety and tolerability of hbv-001 d1 in healthy adult subjects.

this is a single-center, double-blind, randomized, phase 1 study to assess the safety and tolerability of hbv-001 d1 in healthy adult subjects. this will be an upward titration of two dose levels of hbv-001 d1 (10 µg and 50 µg of den1-80e) in 16 subjects across two cohorts. participants in each cohort will receive hbv-001 d1 vaccine or placebo on visits 1, 3 and 5.

Eligibility criteria:
inclusion criteria: * males or females age 18 to 45. * body weight ≥ 110 pounds (50 kg). * satisfactory medical condition established by medical history and physical examination. * females must be of non-child bearing potential (i.e., surgically sterile) or, if of child-bearing potential must be abstinent or willing to employ adequate means of contraception. exclusion criteria: * positive serum test for hiv, hepatitis b surface antigens (hbsag) and/or hepatitis c antibodies. * abuse of drugs or alcohol within 12 months prior to screening. * use of corticosteroids or immunosuppressive drugs within 30 days of screening (use of topical or nasal corticosteroids is allowed). * any confirmed or suspected immunosuppressive or immunodeficient condition. * receipt of any vaccination within 30 days prior to screening. * receipt of blood products within 6 months of screening. * previous flavivirus vaccination (e.g., japanese encephalitis or yellow fever) or flavivirus vaccination planned during the study period. * history of flavivirus infection. * no easy access to a fixed or mobile telephone. * history of residing in a country endemic for dengue, japanese encephalitis virus, or yellow fever virus for a period of \> 1 year. * donation of ≥ 450 ml of blood within the previous 12 weeks.

Keywords: dengue fever dengue hemorrhagic fever dengue shock syndrome vaccine hawaii biotech
tamoxifen study

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Hypertension; Myocardial Ischemia

Summary: to assess the impact of tamoxifen on development of breast cancer, coronary heart disease, and bone fractures. the national cancer institute initiated the prevention trial under its national surgical adjuvant breast and bowel project (nsabp). the national heart, lung, and blood institute provided support to obtain blood pressure and lipid measurements, and lipoprotein and selected coagulation factor measurements in a subsample.

background: tamoxifen is nominally called an 'anti-estrogen' although it has some estrogen-agonist activities and tends to increase plasma endogenous estrogen levels. several studies have confirmed that it decreases plasma total cholesterol and ldl-cholesterol and a review of mortality in patients taking tamoxifen as adjuvant therapy for breast cancer indicates a decreased number of vascular deaths in women on tamoxifen compared to those not on this agent. design narrative: subjects were randomized to receive 10 mg of tamoxifen two times a day or to placebo. the primary endpoint was prevention of invasive breast cancer. the secondary endpoint was the effects on fatal and nonfatal cardiovascular events (coronary heart disease, stroke, and thromboembolic disease) and fractures. a total of 13,388 women at increased risk for breast cancer were randomly assigned to receive either tamoxifen (20 milligrams per day) or placebo. cardiovascular follow-up was available for 13,194 women. the median follow-up was 57 months; the mean follow-up was 49 months. during long-term follow-up, 76 percent of the tamoxifen participants were compliant with the study therapy; 83 percent were compliant through 24 months of follow-up. to evaluate the effects of tamoxifen in women with and without pre-existing heart disease, the 13,388 women enrolled at the 131 clinical sites were divided into subgroups of those with and without a self-reported history of clinical coronary heart disease, defined as myocardial infarction or angina prior to randomization. medical records for subjects with suspected cardiovascular events were collected by the clinical sites and forwarded to the nsabp operations center for adjudication by investigators who were blinded to treatment assignment. primary cardiovascular events included fatal myocardial infarction, q-wave myocardial infarction, and non-q-wave myocardial infarction. secondary cardiovascular events included unstable angina (angina requiring hospitalization) and severe angina (angina requiring revascularization). all subjects were included in the analysis using the intent-to-treat principle.

Eligibility criteria:
women over the age of 35 with a 5-year predicted breast cancer risk of at least 1.66 percent or a history of lobular breast carcinoma in situ, life expectancy of 10 years or more, breast examination and mammogram without evidence of cancer, no hormonal therapy within three months prior to randomization, and no history of deep venous thrombosis or pulmonary embolism. .
assistive technology and reduced caregiver burden

Conditions: Alzheimer Disease; Dementia; Caregiver Burden; Quality of Life; Activities of Daily Living

Summary: the study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with alzheimer's disease and related dementias. family caregivers used assistive technology in the form of visual mapping software on smart devices in the experimental condition to support their care recipients in carrying out activities of daily living. family caregivers in the control condition viewed educational videos about dementia care on their devices in supporting their individuals. the intervention was implemented for a total of 6 weeks. the investigators hypothesized that compared to the caregivers using educational videos, the caregivers using assistive technology will report improved quality of life and completion of activities of daily living for their care recipients, all the while reducing caregiver's burden and stress.


Eligibility criteria:
inclusion criteria: * individual diagnosed with alzheimer's disease or other related dementia (adrd) * participating caregiver of individual with dementia must be the primary caregiver * proficient in english exclusion criteria: * individual not diagnosed with adrd * participating caregiver of individual with dementia is not the primary caregiver * not proficient in english

Keywords: alzheimer disease dementia caregiver burden activities of daily living assistive technology
transcutaneous electrical nerve stimulation (tens) for pain management with medication abortion through 70 days' gestation

Conditions: Abortion in First Trimester

Summary: this is a double-blinded, randomized, placebo-controlled trial evaluating the use of high-frequency transcutaneous electrical nerve stimulation (hftens) compared to sham tens for pain control during medication abortion with mifepristone and misoprostol through 70 days' gestation.


Eligibility criteria:
inclusion criteria: * patients seeking medication abortion with a definite, singleton, intrauterine pregnancy (iup) \< 70 days' gestation on ultrasound * rapid estimate of adult literacy in medicine-short form (realm-sf)22 score \> 4 * age equal to or greater than 18 years * provide informed consent to participate * willing to adhere to study procedures, including access to a smart phone, ability to receive text messages and answer online surveys on smart phone exclusion criteria: * contraindication to medication abortion * allergy to mifepristone or misoprostol * contraindication or allergy to ibuprofen * history of cardiac arrhythmia * presence of an implantable device with electrical discharge, i.e. cardiac pacemaker * history of chronic pain disorder * any opioid use during previous 30 days * current or prior use of tens * bmi \> 30
nerve sparing versus non nerve sparing robot-assisted radical cystectomy-orthotopic ileal neobladder for bladder cancer in the male

Conditions: Bladder Cancer

Summary: to compare the perioperative, functional, and oncologic outcomes between non nerve sparing and nerve sparing robot-assisted radical cystectomy with orthotopic ileal neobladder in male patients with bladder cancer.

this study will enroll male patients with bladder cancer who will undergo robot-assisted radical cystectomy with orthotopic ileal neobladder. the patients will be distributed into two comparable groups according to surgical procedures: non nerve sparing group and nerve sparing group. patient demographic and pathologic, perioperative, functional, and oncologic outcomes will be compared between the two groups.

Eligibility criteria:
inclusion criteria: 1. male patients aged 18 or older. 2. patients those who are diagnosed with urothelial carcinoma. 3. patients those who are capable of receiving radical cystectomy with orthotopic ileal neobladder. 4. patients those who are able to cooperate and complete the follow-up. 5. patients those who volunteer to participate in this study and sign the informed consens. exclusion criteria: 1. patients thsoe who are diagnosed distant metastasis before surgery. 2. patients those who are diagnosed with other malignancies. 3. patients those who had received pelvic radiotherapy or major pelvic operation.
a study to learn about the study medicine called zavegepant (pf-07930207) in children with a history of migraine

Conditions: Acute Treatment of Migraine

Summary: the purpose of the study is to learn about safety and how the body processes the study medicine called zavegepant (pf-07930207) in children with a history of migraine. this study helps understand how the medicine is changed and removed from the body after taking it. this study is seeking participants who: * are children aged between 6 and less than 12 years old * have had migraine for at least 6 months. * weigh more than 15 kilograms all participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). the dose of the study medicine that each participant receives will depend on how much the participant weighs. the study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine. participants will take part in this study for up to 10 weeks. during this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.


Eligibility criteria:
inclusion criteria: 1. participants aged 6 years to less than 12 years. 2. documented medical history of migraine with or without aura for at least 6 months before the screening visit. 3. weight \>15 kg at the screening visit exclusion criteria: 1. evidence or history of clinically significant disease. 2. continuous migraine (defined as an unrelenting headache) within 1 month prior to screening visit. 3. atypical migraine types, complications of a migraine, or a confounding and clinically significant pain syndrome. 4. conditions that may affect the administration or absorption of the nasal product 5. any psychiatric condition that is uncontrolled and/or untreated, including: * clinically significant depression (promis parent proxy sf 2.0 depressive scale t score ≥70) * suicidal ideation and behaviour (c-ssrs: any "yes" to items 2 to 5 or any "yes" to suicide behaviours) 6. serum total bilirubin \>1.5 × uln (upper limit of normal), ast (aspartate transferase) or alt (alanine transaminase) \>2 × uln 7. abnormal ecg (electrocardiogram) at screening visit

Keywords: migraine zavegepant pediatric
analysis of prognostic cell signaling factors in adolescent idiopathic scoliosis

Conditions: Adolescent Idiopathic Scoliosis

Summary: the purpose of this study is to identify potential markers for curve progression in adolescent idiopathic scoliosis (ais). despite its prevalence and impact on child health, the etiology of ais and molecular mechanisms underlying its development and progression remain poorly understood. clinical criteria and features cannot adequately predict which children, diagnosed with mild disease, will undergo subsequent curve progression requiring intervention. the investigators hypothesize that alterations in specific genetic markers will be correlated with the progression of ais curves over time. thus, these markers could be used in the future to develop a reliable, inexpensive and relatively non-invasive cell based diagnostic test to (1) predict spinal curve progression in ais, (2) select patients likely to benefit from early surgical intervention, and (3) potentially screen for asymptomatic children at risk of developing idiopathic scoliosis.


Eligibility criteria:
inclusion criteria: * females aged 10-13 years * diagnosed with mild-moderate spine deformity (cobb angle 15-30 degrees) exclusion criteria: * patients with scoliosis other than idiopathic * trauma * inflammatory disease * malignancies * diabetes * history of previous spine surgery
functional outcomes of an accelerated rehabilitation protocol for acl reconstruction in amateur athletes

Conditions: ACL Injury; Rehabilitation After ACL Reconstruction; Accelerated Protocol

Summary: the main goal of a rehabilitation program after an acl reconstruction is to regain mobility and muscle function and ultimately to return to sports participation. purpose of the study: to investigate the effect of the accelerated rehabilitation program on knee pain, and function in patients post aclr surgery. fifty adult amateur males athletes who underwent aclr surgery participated in this study, their age ranged from 18 to 35years.they were randomly assigned into two equal groups. group (a) received accelerated rehabilitation protocol and group (b) received conventional physical therapy program. treatment sessions were conducted 5 times per week for 22 weeks for both groups. all patients assessed pre and post treatment for pain intensity using visual analogue scale (vas), and knee function using knee injury and osteoarthritis outcome score (koos), knee effusion, and lsi of hop test.


Eligibility criteria:
inclusion criteria: * patients were participated in this study if they fulfilled the following criteria: * underwent pre-operative rehabilitation program with minimal knee effusion and full extension, good patellofemoral mobility, and the patient can actively control the quadriceps. * have an aclr with an autolongous hamstring (ht) graft. * age range from 18-40 years old. * football players or who perform physically demanding work. * have no other ligamentous injury. * have nomeniscectomy previous to or simultaneouswith aclr. * have no cartilage damage. exclusion criteria: * • patients younger than 18 or older than 35 years old * have aclr with any graft other than hamstring (ht) graft * have acl revision surgery * have other ligamentous injury * have a meniscectomy previous to or simultaneous with aclr. * had meniscal repair simultaneously with aclr * have cartilage damage.
smartphone assessment prior radial artery harvesting for cabg

Conditions: Coronary Artery Disease

Summary: coronary artery bypass graft (cabg) surgery is a procedure where surgeons use blood vessels from elsewhere in the body to go around blockages or narrowings in the heart arteries. before the surgery, the surgeon needs to choose which vessel will be used for the bypass, including potentially the radial artery in the wrist. smartphones have been shown in a previous study to be a better way to assess the arteries in the hand than the traditional physical examination, as it is less subjective than simply watching the flushing of the hand. in this study, the investigators will assess the utility of a smartphone application in determining whether there is enough blood flow in the hand prior to using the radial artery for cabg surgery.

coronary artery bypass graft (cabg) surgery is a procedure where surgeons use blood vessels from elsewhere in the body to go around blockages or narrowings in the heart arteries. before the surgery, the surgeon needs to choose which vessel will be used for the bypass, including potentially the radial artery in the wrist. before using this artery, it is important to ensure that there is enough blood flow to the hand to prevent complications. the best way to do this involves the use of ultrasound, but this takes a long time and its availability can be limited. therefore, the assessment is usually done at the bedside by examining the hand, which relies on the doctor watching the flushing of the hand during compression and release of the artery. currently, smartphones with cameras are able to assess blood flow by passing light through the skin and observing differences in brightness. this has been shown in a previous study to be a better way to assess the arteries in the hand than the traditional examination, as it is less subjective than simply watching the flushing of the hand. in this study, the investigators will assess the utility of a smartphone application in determining whether there is enough blood flow in the hand prior to using the radial artery for cabg surgery.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years old * scheduled to undergo coronary artery bypass graft for which the surgeon is considering the use of a radial artery conduit * able and willing to provide written informed consent exclusion criteria: * hemodynamic instability * need for emergent cardiac surgery * known previous removal of the radial or ulnar arteries

Keywords: smartphone coronary artery bypass grafting modified allen's test
artificial intelligence-based video analysis to detect infantile spasms

Conditions: Infantile Spasms

Summary: infantile spasms are a type of seizure linked to developmental issues. unfortunately, they are often misdiagnosed, causing delays in treatment. the purpose of this study is to develop a computer program that can reliably differentiate infantile spasms from similar, yet benign movements in videos. this computer program will learn from videos taken by parents of study participants. quickly recognizing and treating infantile spasms is crucial for ensuring the best developmental outcomes.


Eligibility criteria:
inclusion criteria: * participant age less than 24 months * participant evaluated in the johns hopkins outpatient center, johns hopkins pediatric emergency department or johns hopkins inpatient units due to spells of abnormal movement or seizure * participant evaluated by a pediatric neurologist during the outpatient or inpatient visit at johns hopkins hospital * at least one video recording of the spell of abnormal movement produced by the parent/guardian available for provider review exclusion criteria: * poor video recording quality * entire patient is not in frame

Keywords: seizure epilepsy infantile spasm epileptic spasm west syndrome hypsarrhythmia artificial intelligence video analysis computer vision machine learning
a phase 2 study of mze829 in adults with apol1 kidney disease

Conditions: Proteinuric Kidney Disease

Summary: this is purpose of this study is to evaluate the safety, tolerability, and effect on albuminuria of mze829 in adults with apol1 kidney disease

an open-label phase 2 study is designed to evaluate the safety, tolerability, and effect on albuminuria of mze829 in adults with proteinuric chronic kidney disease and the apol1 high risk genotype.

Eligibility criteria:
key inclusion criteria: * apol1 high risk genotype of g1/g1, g2/g2, or g1/g2 * chronic kidney disease with persistent albuminuria key exclusion criteria: * organ or bone marrow transplantation * history of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * conditions that may alter drug absorption, e.g., history of bariatric surgery * type i diabetes * pregnant or currently nursing other inclusion/exclusion criteria defined in protocol apply.

Keywords: apol1-mediated kidney disease (amkd) apol1 kidney disease (akd)